Synthesis and Preclinical Evaluation of Three Novel 68Ga-Labeled Bispecific PSMA/FAP-Targeting Tracers for Prostate Cancer Imaging
Molecules · 2023
DOI: 10.3390/molecules28031088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Arsyangela Verena und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Tumor heterogeneity limits the efficacy and reliability of monospecific radiopharmaceuticals in prostate cancer diagnosis and therapy. To overcome this limitation and improve lesion detection sensitivity, we developed and evaluated three bispecific radiotracers that can target both prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP), which are the two key proteins overexpressed in prostate cancer. Three FAP-targeting ligands with various linker lengths were synthesized through multistep organic synthesis, and then connected to the PSMA-targeting motif. IC50(PSMA) and IC50(FAP) values of Ga-complexed bispecific ligands, Ga-AV01017, Ga-AV01030, and Ga-AV01038 were 25.2–71.6 and 1.25–2.74 nM, respectively. The uptake values in PSMA-expressing LNCaP tumor xenografts were 4.38 ± 0.55, 5.17 ± 0.51, and 4.25 ± 0.86 %ID/g for [68Ga]Ga-AV01017, [68Ga]Ga-AV01030, and [68Ga]Ga-AV01038, respectively, which were lower than the monospecific PSMA-targeting tracer [68Ga]Ga-HTK03041 (23.1 ± 6.11 %ID/g). The uptake values in FAP-expressing HEK293T:hFAP tumor xenografts were 2.99 ± 0.37, 3.69 ± 0.81, 3.64 ± 0.83 %ID/g for [68Ga]Ga-AV01017, [68Ga]Ga-AV01030, and [68Ga]Ga-AV01038, respectively, which were also lower than the monospecific FAP-targeting tracer, [68Ga]Ga-FAPI-04 (12.5 ± 2.00 %ID/g). We observed that the bispecific tracers had prolonged blood retention, in which tracers with a longer linker tend to have a higher blood uptake and lower tumor uptake. Further investigations are needed to optimize the linker selection to generate promising bispecific PSMA/FAP-targeting tracers for prostate cancer imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.
- Department of Radiology, University of British Columbia, Vancouver, BC V5Z1M9, Canada.
- Department of Functional Imaging, BC Cancer, Vancouver, BC V5Z4E6, Canada.
ORCID-Profile: Arsyangela Verena, Antonio A W L Wong, Kuo-Shyan Lin
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Verena, A., Zhang, Z., Kuo, H. T., Merkens, H., Zeisler, J., Wilson, R., Bendre, S., Wong, A. A. W. L., Bénard, F., & Lin, K. S. (2023). Synthesis and Preclinical Evaluation of Three Novel 68Ga-Labeled Bispecific PSMA/FAP-Targeting Tracers for Prostate Cancer Imaging. Molecules. https://doi.org/10.3390/molecules28031088
Vancouver
Verena A, Zhang Z, Kuo HT, Merkens H, Zeisler J, Wilson R, et al. Synthesis and Preclinical Evaluation of Three Novel 68Ga-Labeled Bispecific PSMA/FAP-Targeting Tracers for Prostate Cancer Imaging. Molecules. 2023. doi:10.3390/molecules28031088
BibTeX
@article{Verena2023,
author = {Verena, Arsyangela and Zhang, Zhengxing and Kuo, Hsiou-Ting and Merkens, Helen and Zeisler, Jutta and Wilson, Ryan and Bendre, Shreya and Wong, Antonio A W L and Bénard, François and Lin, Kuo-Shyan},
title = {Synthesis and Preclinical Evaluation of Three Novel 68Ga-Labeled Bispecific PSMA/FAP-Targeting Tracers for Prostate Cancer Imaging},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28031088}
}
EUVIMED